Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Immune Globulin PID (Jan 2019)

Posted by Matt Breese on Jan 4, 2019

Find me on:

According to our recent payer coverage analysis for immune globulins for primary immunodeficiency (PID), combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A market access breakdown reveals that more than 38% of the covered lives under the pharmacy benefit in commercial and health exchange formularies have utilization management restrictions 

MMIT-Reality Check-PID_1Q2019

Source: MMIT data as of Q1 2019

Trends: The FDA gave an additional approval to Hizentra (immune globulin subcutaneous [human]) as a maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy to prevent relapse of neuromuscular disability and impairment

To read the full Reality Check on Immune Globulin (PID) treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 

MMIT-RC_Thumbnail_1-1.pngView Reality Check

Topics: Specialty, Market Access, Branding & Marketing